Drug Discovery

Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects. Read More

Vanderbilt University Medical Center (VUMC), Vanderbilt University and Japan-based Ono Pharmaceutical Co. Ltd. have expanded a drug discovery agreement initiated in 2015 that will now run through 2019. Read More

Geneticists have developed an effective new method for identifying the genes that produce the chemicals plants use to protect themselves from predators, which are an important natural drug source. Read More

A detailed structural and functional analysis of the yeast protein that is the main target of antifungal drugs will help direct efforts to develop better treatments. Read More

Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center. Read More

Vanderbilt University has been selected as one of seven Dedicated Centers in the nation for the next phase of the Chemical Biology Consortium (CBC), a national network of scientists on the leading edge of cancer drug discovery. Read More

The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers reported May 2 in Nature Methods. Read More

A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation. Read More

Vanderbilt University Medical Center and Ono Pharmaceutical Group, an international company based in Japan, have signed a drug discovery agreement. Read More

Structural and molecular details of an anti-fungal target's interaction with inhibitors suggest ways to design better treatments for fungal infections. Read More

La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders. Read More

Vanderbilt investigators have developed a new algorithm to understand the networks of signaling molecules that control drug action. Read More

Inhibitors of the enzyme phospholipase D1 suppress the replication of HIV-1, Vanderbilt investigators have discovered. Read More

Vanderbilt University is partnering with the William K. Warren Foundation of Tulsa, Oklahoma, on research aimed at improving the treatment of schizophrenia and other forms of serious mental illness. Read More

New findings underscore the attractiveness of the HIV capsid – the structure that encloses the viral genome – as a therapeutic target. Read More

A family of single-celled organisms that thrive in environments too extreme for most other species to survive may be an untapped source of new antibacterial drugs. Read More

A receptor in the brain that regulates appetite and body weight has now been found in L cells, key regulatory cells in the gut, providing the pharmaceutical industry with a novel drug target for both obesity and diabetes, a Vanderbilt University-led research team reported this week. Read More

A Vanderbilt lung cancer patient’s exceptional response to different types of therapies spurred research that suggests lung cancer patients with specific gene alterations may benefit from combination therapy that targets two different cancer pathways. Read More

Compounds developed at Vanderbilt University may offer a new way to block influenza infection. Read More

Inhibition of BMP growth factor signaling reduces breast tumor burden and metastasis. Read More